Compare Eni SpA (E) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Vertex Pharmaceuticals Incorporated — how do they compare? Eni SpA trades at $56.09 (market cap $79.81B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Eni SpA pays a 4.39% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| E | VRTX | |
|---|---|---|
Market Cap | $79.81B | $127.55B |
Volume | 365,912 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $57.61 | $557.96 |
52-Week Low | $34.03 | $407.37 |
Typical Hold Time | 53 Days | 120 Days |
Enterprise Value | $104.34B | $121.68B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $53.96, down 1.08% on the day, amid a bearish technical signal and mixed earnings performance. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97%. Recent news highlights strategic moves in humanoid robotics, LNG projects, and fuel discounts. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85, while cash flow remains positive but net cash flow turned negative in 2026 projections.
The outlook is cautious; low valuations and dividend payments offer value, but revenue declines and earnings misses pose risks. Analyst consensus is mixed with 34.62% buy ratings. Key risks include energy price volatility and execution of new tech initiatives. Further upside depends on stabilizing revenue and meeting earnings expectations.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
